Hospital Corporation of China Ltd. reported its financial results for the six months ended 30 June 2025. Revenue totaled RMB743.0 million, an increase of 3.3% compared to RMB719.5 million in the same period last year, primarily driven by higher revenue from general hospital services to individual patients. Gross profit for the period was RMB147.1 million, down from RMB152.6 million a year earlier. Adjusted gross profit, which excludes expenses related to share-based awards and depreciation and amortisation of identifiable assets from acquisitions, was RMB155.0 million, a decrease of 4.2% compared to the prior period. The company reported a net profit of RMB168.6 million for the period, compared to RMB23.6 million in the previous year. Adjusted net profit reached RMB70.6 million, down from RMB87.3 million in the same period last year, after excluding impacts from interest expenses on convertible bonds, gain on modification of convertible bonds, foreign exchange losses, and depreciation and amortisation of identifiable assets from acquisitions. During the reporting period, sales of pharmaceutical products amounted to RMB4.3 million, a decrease from RMB4.4 million in the previous year, while other sales were RMB1.2 million, compared to RMB1.3 million last year. The company stated that it will continue to expand collaborations with advanced service providers in precision medicine and focus on offering supplementary services for families of patients within the public basic healthcare system.